Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With CancerJune 20, 2016
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Limited radiotherapy effective after low-risk tumors are removed, but questions remain.
An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.
Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
The metabolism of pancreatic cancer cells is altered by the anticancer activity of CDK4/6 inhibitors. Researchers hope this biologic vulnerability could be exploited to treat pancreatic cancer.
Dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations have been suggested by the largest analysis of breast cancer cell function to date.
Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Lung cancers with KRAS-related gene mutations might benefit from a triple therapy regimen of 2 experimental drugs plus radiation therapy.
Palbociclib, a new oral treatment for certain types of breast cancer, demonstrates potential as a treatment for other types of cancer as well.
- PMPS: A Common Late Effect of Surgery and Radiation for Breast Cancer
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Physical Activity May Reduce Mortality by 44% in Patients With Breast Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
- Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer
- Nurses Are Key to Referrals to Inpatient Integrative Medicine Services
- Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma
- Poor Compliance to Adjuvant Chemo Linked to Poorer Survival in Rectal Cancer
- Users Support Indoor Tanning Device Age Restrictions, Stronger Health Warnings, But Not Total Ban
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|